Literature DB >> 7176332

Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal disease.

C Beretta-Piccoli, P Weidmann, H Schiffl, C Cottier, F C Reubi.   

Abstract

The cardiovascular pressor responsiveness to infused norepinephrine (NE) or angiotensin II (AII) as related to endogenous plasma NE or renin levels was assessed in 20 patients with mild parenchymal kidney disease (plasma creatinine 2.20 +/- 0.58 mg/dl, +/- SEM) and in 20 normal subjects approximately matched for sex and age. The two groups did not differ significantly in mean body weight, heart rate, blood volume, plasma electrolytes, exchangeable or urinary sodium, plasma aldosterone, epinephrine and renin levels, or AII threshold or pressor doses. Basal (including pre-infusion) plasma NE levels, the relationship between plasma NE measured during NE infusion and the corresponding NE infusion rate, as well as the total plasma clearance of NE (5.0 +/- 0.8 vs. 5.5 +/- 0.5 liter/min) also did not differ significantly between the two groups. In contrast, the threshold or pressor doses of infused NE decreased significantly in the patients with kidney disease (94 +/- 11 vs. 134 +/- 14 ng/kg/min and 21 +/- 3 vs. 40 +/- 7 ng/kg/min; P less than 0.05). Moreover, based on analysis of covariance, the individual pressor doses as related to basal plasma NE levels were distributed differently (P less than 0.01) between the patients and normal subjects. These findings suggest that the kinetics of plasma NE are unaltered largely in early stage kidney disease. However, such patients tend to develop an exaggerated pressor responsiveness to NE in the presence of normal plasma NE levels. This disturbance may favor the development of hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7176332     DOI: 10.1038/ki.1982.169

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

Review 1.  Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.

Authors:  D A Sica; T W Gehr; A Fernandez
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Modulation of platelet Ca2+ homeostasis by hypertensive plasma factor(s) derived from patients with early-stage renal disease.

Authors:  H Schiffl
Journal:  Klin Wochenschr       Date:  1991-12-11

3.  Platelet cytosolic free calcium concentration in hypertension associated with early stage kidney disease.

Authors:  H Schiffl
Journal:  Klin Wochenschr       Date:  1989-07-03

Review 4.  Chronic Kidney Disease and Atrial Fibrillation: A Contemporary Overview.

Authors:  Nitin Kulkarni; Nilusha Gukathasan; Samantha Sartori; Usman Baber
Journal:  J Atr Fibrillation       Date:  2012-06-15

5.  Vascular α1-adrenergic sensitivity is enhanced in chronic kidney disease.

Authors:  Justin D Sprick; Doree L Morison; C Michael Stein; Yunxiao Li; Sachin Paranjape; Ida T Fonkoue; Dana R DaCosta; Jeanie Park
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-07-17       Impact factor: 3.619

6.  Effect of medial calcification on vascular function in uremia.

Authors:  Roy L Sutliff; Erik R Walp; Alexander M El-Ali; Stacey Elkhatib; Koba A Lomashvili; W Charles O'Neill
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-06

7.  Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness.

Authors:  H Schiffl; P Weidmann; C Beretta-Piccoli; C Cottier; A J Seiler; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 8.  Renal sympathetic nervous system and the effects of denervation on renal arteries.

Authors:  Arun Kannan; Raul Ivan Medina; Nagapradeep Nagajothi; Saravanan Balamuthusamy
Journal:  World J Cardiol       Date:  2014-08-26

9.  [Sympathetic activity in terminal renal failure and kidney transplants].

Authors:  R Lang; J Michels; R Becker-Berke; K Lukowski; V Vlaho; R Grundmann
Journal:  Klin Wochenschr       Date:  1984-11-02

10.  Hypertension Secondary to PHPT: Cause or Coincidence?

Authors:  Helmut Schiffl; Susanne M Lang
Journal:  Int J Endocrinol       Date:  2011-03-07       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.